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Abstract 
Background. Organ motion during treatment delivery in radiotherapy (RT) may lead to deterioration of the 
planned dose, but can be mitigated by dynamic multi-leaf collimator (DMLC) tracking. The purpose of 
this study was to implement and experimentally validate a method for time-resolved motion including dose 
reconstruction for volumetric modulated arc therapy (VMAT) treatments delivered with and without DMLC 
tracking.  
Material and methods. Tracking experiments were carried out on a linear accelerator (Trilogy, Varian) 
with a prototype DMLC tracking system. A motion stage carrying a biplanar dosimeter phantom 
(Delta4PT, Scandidos) reproduced eight representative clinical tumor trajectories (four lung, four prostate). 
For each trajectory, two single-arc 6 MV VMAT treatments with low and high modulation were delivered to 
the moving phantom with and without DMLC tracking. An existing in-house developed program that adds 
target motion to treatment plans was extended with the ability to split an arc plan into any number of sub-arcs, 
allowing the calculated dose for different parts of the treatment to be examined individually. For each VMAT 
sub-arc, reconstructed and measured doses were compared using dose differences and 3%/3 mm γ-tests. 
Results. For VMAT sub-arcs the reconstructed dose distributions had a mean root-mean-square (rms) dose 
difference of 2.1% and mean γ failure rate of 2.0% when compared with the measured doses. For final 
accumulated doses the mean rms dose difference was 1.6% and the γ failure rate was 0.7%.  
Conclusion. The time-resolved motion including dose reconstruction was experimentally validated for 
complex tracking and non-tracking treatments with patient-measured tumor motion trajectories. The 
reconstructed dose will be of high value for evaluation of treatment plan robustness facing organ motion 
and adaptive RT. 
 
 
 
 
 
Introduction 
 
In radiotherapy (RT), organ motion during treatment delivery may lead to deterioration of the planned dose 
distribution [1,2]. A promising method to account for the intrafraction motion is dynamic multi-leaf 
collimator (DMLC) tracking where the planned MLC aperture is continuously adapted to the real-time 
monitored target position [3–6]. Motion including dose reconstruction is possible for tumor tracking since 
the required knowledge of intrafraction target motion is readily available. One avenue towards motion 
including dose reconstruction is the utilization of a clinical treatment planning system (TPS). This approach 
allows use of institutionally validated dose calculation algorithms and evaluation of the reconstructed dose in 
the clinical environment. 
Several methods have been proposed to estimate the impact of rigid tumor motion with a commercial TPS by 
convolving the probability density function (PDF) of the target position with either the static three-
dimensional (3D) dose distribution [7,8] or the incident  two-dimensional (2D) photon fluence of each treatment 
beam [9–11]. However, convolution methods cannot account for interplay effects in dynamic RT treatments 
where MLC motion takes place during beam-on periods. An alternative method is to model target motion by 
isocenter shifts [12,13]. In a previous paper, a simple and automatic method that models target motion by splitting 
the original treatment fields into a multitude of sub-beams with different isocenter shifts was presented [14]. 
In this study we refine this method with temporal resolution by allowing reconstruction of the target dose 
distribution at several time points throughout delivery of a VMAT field to a moving target and validate it 
experimentally for complex treatments. 
 
 
Material and methods 
Experiments 
Electromagnetic (EM)-based DMLC tracking experiments were carried out on a Trilogy linear accelerator 
equipped with a 120 leaf Millennium MLC (Varian Medical Systems, CA, USA) and a prototype DMLC 
tracking system [4]. A schematic representation of the experiment setup is provided in Supplementary 
Figure 1. During experiments, a Delta4PT phantom (Scandidos, Sweden) [15] with two orthogonal planar 
diode arrays (total of 1069 diodes) encased in cylindrical PMMA measured the delivered time-resolved 
dose distribution at a rate of 72 Hz. Routine clinical calibration of the Delta4PT phantom was performed prior 
to measurements. 
As described in the Supplementary Appendix, a programmable motion stage [16] was modified to carry the 
phantom on a platform made of wood. The motion stage reproduced eight patient-measured tumor trajectories 
representing different motion patterns; four lung trajectories (“Typical” motion, High- frequency breathing, 
Predominantly left-right motion, and Baseline shifts) and four prostate trajectories (Continuous drift, Persistent 
excursion, Transient excursion, and High-frequency excursions). A detailed explanation of the tumor 
trajectories and their selection can be found in Keall et al. [17]. For each trajectory, two 358° single arc 6 MV 
RapidArc VMAT plans with low and high modulation were delivered to the moving phantom. Details of the 
VMAT plans have been published previously [17,18]. The VMAT treatments were delivered for each trajectory 
with and without DMLC tracking, as well as to a static phantom for reference. 
The 3D target position was measured at 30 Hz by an EM transponder system (RayPilot, Micropos Medical, 
Sweden). During tracking the position was transmitted to the tracking software for continuous adaptation of the 
MLC aperture. For lung tumor trajectories, prediction was used to compensate for the tracking system latency, 
which was previously measured to be 140 ms [19]. Tracking log files with the gantry angle and real-time 
measured target position and Dynalog files [20] with the MLC positions, gantry angle, and beam-on flag were 
stored for each experiment along with the time-resolved Delta4PT phantom measurements. 
 
 
Dose reconstruction and comparison with measurements 
The data flow is illustrated in Supplementary Figure 2. The dose delivered in each treatment was reconstructed and 
compared with the measured dose distribution. The dose reconstruction was made with a previously published method 
that mimics target motion as isocenter shifts [14], and which was expanded for this study to allow dose reconstruction 
for any division of a VMAT field into sub-arcs. In the current study, the 358° VMAT fields were divided into 10 
sub-arcs of 35.8°, resulting in a relatively coarse time resolution with the reconstructed dose distribution 
determined for each individual tenth of the VMAT treatments. First, the Dynalog files of each experiment were 
synchronized to the tracking log files (and thereby the phantom motion) by use of the gantry angle. Next, an in-
house developed computer program (written in Matlab, MathWorks Inc., MA, USA) was used to generate a 
motion mimicking Dicom treatment plan with the actual MLC positions recorded in the Dynalog files and a 
multitude of sub-beams with isocenter shifts that corresponded to the real-time recorded target positions. Unlike 
Poulsen et al. [14], the Dynalog recorded MLC positions were used in the dose reconstruction not only for 
tracking, but also for non-tracking treatments. A bin width of 1 mm was used, i.e. all measured target positions 
within a 1 mm3 cube were given the same isocenter shift. Each motion mimicking Dicom plan had 
approximately 1500 control points. 
The motion mimicking treatment plan was imported into the treatment planning system (Eclipse 10.0.28, Varian 
Medical Systems), where the motion including dose distribution was calculated using the Anisotropic Analytical 
Algorithm (AAA) and subsequently exported as a 3D dose matrix for each sub- beam in a grid with voxels of 2.5 
mm sides. Next, a second in-house developed Matlab program added all sub-beam dose matrices belonging to 
each VMAT sub-arc, thus creating the 3D dose distribution delivered during each sub-arc (i.e. during each tenth of 
the VMAT field). 
In order to compare the reconstructed doses with the measurements, the dose at the discrete positions of the Delta4PT 
phantom diodes was extracted from the reconstructed 3D dose distributions correcting for small spatial offsets 
caused by slight off-isocenter positioning of the phantom. For temporal synchronization of measured and 
reconstructed doses, the phantom data were synchronized with the treatment delivery by means of the beam-on 
flag in the Dynalog files. Measured doses were then accumulated for each VMAT sub-arc producing 10 doses 
to compare with the reconstructed doses. At posterior gantry angles the entrance beam passed through the couch, 
the EM antennae system, and the platform carrying the phantom. The damping of these objects was measured as a 
function of gantry angle for the central diode in the phantom and used as a common gantry dependent correction 
factor for the measured dose for each diode. 
The reconstructed dose distributions were com- pared with the diode measurements for each sub-arc, and for the 
accumulated dose of the complete arc field, by means of the dose difference and a γ-test [21] with the 3%/3 
mm pass criteria used for daily quality assurance (QA) in our clinic. The root-mean- square (rms) dose difference 
was determined in percentage of the maximum measured dose for the sub-arc (or complete arc field). The γ 
value was calculated for each diode using the 2D distance to agreement in the diode planes. Diodes with 
accumulated measured doses below 5% of the maximum accumulated dose in the measured static reference 
were excluded in the calculations of both dose differences and γ-tests. Statistical significance analysis of 
differences in rms dose differences and γ failure rates for sets of experiments used a two-sample Student’s t-test 
with a 5% significance level. 
In the interest of investigating the ability of the dose reconstruction to predict the impact of a given target motion on 
a given VMAT plan, the γ failure rate of the reconstructed dose delivered to a moving phantom using the 
reconstructed static phantom dose as reference was calculated and compared with the same γ failure rate 
calculation based on the measured doses. 
 
 
 
 
 
 
 Results 
Figure 1 illustrates the impact of motion on the dose distribution for a selected experiment. Comparison of the left 
and middle columns qualitatively shows that for non-tracking treatment delivery to the moving phantom, the dose 
became smeared out and a systematic shift of the dose in the caudal direction (down in Figure 1) occurred in 
both individual VMAT sub-arcs and the accumulated dose of the complete arc fields. Redistribution of dose 
due to interplay effects was also seen in some sub-arcs. Tracking to a large extent restored the moving phantom 
dose distribution to that of a static phantom (right column). A single diode in the Delta4PT phantom was 
non-functioning. As this diode invariably measured zero dose, it was automatically excluded from 
calculations of dose differences and γ-tests due to the < 5% dose exclusion criterion. 
The time-resolved doses for three sample diodes in Figure 2 show that phantom motion had a large effect on the 
doses near high dose gradients (green) for non-tracking treatments, but that this effect was largely reduced by 
tracking. However, motion only marginally disturbed the dose in low dose gradient regions (red, blue) for both 
tracking and non-tracking experiments. For all three sample diodes the time- resolved reconstructed dose was in 
good agreement with the measurements (mean rms difference of 0.7% averaged over all VMAT sub-arcs). 
Averaging over all experiments and all included diodes, doses were reconstructed with a mean rms dose 
difference relative to the experiments of 2.1% for VMAT sub-arcs and of 1.6% for doses accumulated over the 
complete arc fields. Table I presents the rms dose difference for each individual VMAT plan. The mean rms dose 
difference was significantly higher for high modulation VMAT plans than for low modulation plans (p < 0.001 for 
both sub-arcs and the complete arc fields). The mean rms dose difference was also higher for the investigated lung 
plans than for the prostate plans for both individual VMAT sub-arcs (p < 0.001) and doses accumulated over the 
complete arc fields (p = 0.040). The rms dose difference for doses to a moving phantom compared to a static 
phantom was not statistically significant (p = 0.92 for sub-arcs and p = 0.96 for complete arc fields). 
The mean γ failure rate was 1.6% for doses of VMAT sub-arcs and 0.7% for accumulated doses of the complete 
arc fields. Table II lists γ failure rates of the reconstructed dose for each individual VMAT plan. The γ failure 
rates were significantly higher for reconstructed doses of high modulation plans than of low modulation plans 
accumulated over the complete arc fields (p = 0.005) but not for sub-arcs (p = 0.32). The γ failure rates 
were significantly higher for reconstructed doses of lung VMAT plans than of prostate VMAT plans (p < 
0.001) for both VMAT sub-arcs and the complete arc fields. 
As shown in Figure 3 the reconstructed motion induced γ failure rates in the delivered target dose distributions 
(using static doses as reference) in general agreed well with the corresponding γ failure rates in the measured 
doses. The rms deviation between measured and reconstructed γ failure rates was 1.5%. 
 
  
 
 
 
Figure 1. A representative example of measured (M) and reconstructed (R) doses for the high 
modulation volumetric modulated arc therapy (VMAT) lung plan delivered with the high frequency lung 
motion trajectory. The dose in the central 6 X 6 cm of one of the biplanar arrays is displayed for the first 
three VMAT sub-arcs (i.e. first three tenths of the VMAT field) as well as accumulated for the entire VMAT 
field. The three columns show the dose of a static phantom (left), a moving phantom without tracking 
(middle), and a moving phantom with tracking (right). One diode was broken (marked with a black arrow) and 
invariably showed zero in the measured dose.The red arrow marks an example of dose redistribution due to 
interplay effects in this specific VMAT sub-arc. 
  
Figure 2. Measured (curves) and reconstructed (symbols) cumulative doses in three sample diodes in the 
Delta4PT phantom: the diode in the center of the phantom (blue), a diode in a high dose gradient (green), and 
a diode in the periphery of the phantom (red). Doses are shown for the static phantom (full line) as well as the 
moving phantom without (dashed line) and with (dotted line) tracking. Top: high and low modulation lung 
VMAT plans with the high frequency lung tumor motion trajectory. Bottom: high and low modulation 
prostate VMAT plans with the Continuous drift prostate motion trajectory. The central and peripheral diodes 
were the same for all plots, whereas the high dose gradient diode differed between lung and prostate 
VMAT plans. 
 
Table I. Results of dose reconstruction quantified by dose differences to the measured dose. 
 
Plan 
 
Static 
Motion, no 
tracking 
Motion, tracking  
All 
Dose for VMAT 
sub-arcs 
    
Lung, low 
modulation 
2.5% 2.3 [2.0,2.6]% 2.3 [2.2,2.5]% 2.4 [2.0,2.6]% 
Lung, high 
modulation 
2.6% 2.8 [2.4,3.2]% 2.5 [2.3,2.7]% 2.7 [2.3,3.2]% 
Prostate, low 
modulation 
1.5% 1.6 [1.5,1.7]% 1.6 [1.5,1.9]% 1.6 [1.5,1.9]% 
Prostate, high 
modulation 
1.7% 1.9 [1.7,2.0]% 1.8 [1.7,2.0]% 1.8 [1.7,2.0]% 
Accumulated dose for complete arc field 
Lung, low 
modulation 
1.9% 1.7 [1.5,2.0]% 1.7 [1.5,1.8]% 1.7 [1.5,2.0]% 
Lung, high 
modulation 
2.1% 2.2 [1.9,2.3]% 2.0 [2.0,2.1]% 2.1 [1.9,2.3]% 
Prostate, low 
modulation 
0.8% 0.8 [0.8,0.9]% 0.8 [0.7,0.9]% 0.8 [0.7,0.9]% 
Prostate, high 
modulation 
1.6% 1.8 [1.7,2.0]% 1.9 [1.7,2.1]% 1.8 [1.6,2.1]% 
Mean [and range] of root-mean-square dose differences between measured and reconstructed dose distributions in 
percentage of the maximum measured dose, averaged over the four trajectories investigated for each plan. Results are 
shown both for the dose delivered in each VMAT sub-arc (i.e. each tenth of the VMAT field, top four rows) and for 
the complete arc field (bottom four rows). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Discussion 
A method for time-resolved dose reconstruction of moving targets by means of motion mimicking Dicom 
treatment plans was demonstrated and experimentally validated in two orthogonal planes for complex 
rotational RT treatments with and with- out DMLC tracking. The method provided similar agreement between 
reconstructed and measured doses for deliveries to static and moving phantoms with and without tracking, 
indicating that the motion encoded dose reconstruction is on par with that of the well-established and commonly 
applied method for daily QA using the Delta4PT phantom. This accuracy is also available with temporal 
resolution, which enables pinpointing of temporal errors in treatment delivery [22]. The dose reconstruction 
was found to be more challenged by plans with high modulation than with low modulation. Even so, the highest 
mean rms difference between reconstructed and measured dose distributions was 3.2% (high modulation lung 
plan, “Typical” trajectory, averaged over 10 VMAT sub-arcs). 
In this study the dose reconstruction was also found to be more challenging for the investigated lung treatments 
than for prostate treatments, but the cause is not obvious. The difference could be due to the faster and larger 
magnitude of lung tumor motions or the considerable difference in target volume between the lung and prostate 
treatment plans. Other indirect causes for the difference are also possible, such as difference in plan complexity due 
to different OAR being included in the inverse optimization. 
The mean γ failure rates of accumulated reconstructed doses (0.7% with 3%/3 mm pass criteria) are slightly 
higher than those found previously for DMLC tracking of conformal fields (0.5% with 2%/2 mm pass 
criteria) [14], which is to be expected due to the higher plan complexity. Other groups have recalculated doses 
delivered with VMAT using the actual leaf motions from Dynalog files with comparable results [23,24], but 
these studies do not include motion effects or offer temporal resolution. To the best of our knowledge, only one 
previous study provides reconstruction of temporally resolved motion-affected doses [25]. In that study the 
original treatment plan was morphed based on measured data and then perturbed with rigid motion to 
achieve γ failure rates of 90.6–95% (3%/3 mm criteria) for reconstructed doses of moving phantoms. 
In the present study the entirety of the treatment delivery was split into 10 sub-arcs providing relatively coarse 
temporal resolution, but the method could in principle be used to split an RT arc treatment plan into any 
number of smaller sub-arcs. However, the higher temporal resolution comes at the expense of speed and the 
complications of managing large amounts of data. Ideally, the dose reconstruction method should be fast enough 
to allow dose reconstruction and dose error estimations in real time. The present dose reconstruction method is 
also limited by treating tissue motion as rigid translations, ignoring tissue deformations [26–28]. No trajectories were 
available for healthy tissues. Doses to OAR, which often do not move rigidly with the tumor [29], were 
therefore considered outside the scope of the present study. The motion of healthy tissues may also affect the 
dose to the tumor, but such variations are not accounted for in the current study. Although the thorax is highly 
inhomogeneous, both lung and prostate plans were measured and reconstructed using a homogeneous phantom. 
Doing so is, however, in accordance with common QA procedure [15,30]. 
The TPS-based dose reconstruction allows for application of other dose calculation algorithms as well 
[14,31,32] and enables calculation of standard clinical measures of dose coverage, such as dose- volume 
histograms. The method presented here is therefore widely applicable for interfractional adaptive RT, where 
knowledge of dose to a moving target, accumulated over a single or several fractions, could be of value. 
In summary, the time-resolved motion including dose reconstruction was experimentally validated for complex 
tracking and non-tracking treatments. The reconstructed dose will be of high value for evaluation of treatment plan 
robustness facing organ motion and adaptive RT. 
 
 
 
  
Table II. Results of dose reconstruction quantified by γ-tests using measured dose as reference. 
Plan Static 
Motion, no 
tracking Motion, tracking All 
Mean γ failure rates for VMAT sub-arcs 
    
Lung, low modulation 4.60% 3.4 [2.8,3.9]% 3.6 [3.3,4.5]% 
3.6 
[2.8,4.6]% 
Lung, high modulation 2.60% 3.1 [2.4,3.6]% 1.8 [1.5,2.2]% 
2.5 
[1.5,3.6]% 
Prostate, low modulation 0.60% 0.7 [0.5,0.9]% 0.8 [0.5,1.1]% 
0.8 
[0.5,1.5]% 
Prostate, high modulation 0.90% 1.5 [1.3,2.0]% 1.1 [0.9,1.4]% 
1.1 
[0.8,2.0]% 
γ failure rates for complete arc field 
    
Lung, low modulation 1.30% 0.5 [0.3,0.8]% 0.8 [0.3,1.0]% 
0.7 
[0.3,1.3]% 
Lung, high modulation 2.30% 2.3 [1.4,2.7]% 1.5 [0.9,2.1]% 
2.1 
[0.9,2.7]% 
Prostate, low modulation 0.00% 0.0 [0.0,0.0]% 0.0 [0.0,0.0]% 
0.0 
[0.0,0.0]% 
Prostate, high modulation 0.10% 0.1 [0.0,0.6]% 0.1 [0.0,0.3] 
0.1 
[0.0,0.6]% 
     
Mean [and range] of 3%/3 mm γ failure rates of reconstructed dose distributions compared with measurements, 
averaged over the four trajectories investigated for each plan. Results are shown averaged over the ten individual 
VMAT sub-arcs (top four rows) and for the complete arc field (bottom four rows). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 3. 3%/3 mm γ failure rates in the final accumulated dose delivered to the moving target with (closed 
symbols) and without (open symbols) dynamic MLC tracking for lung (squares) and prostate (circles) 
VMAT plans. The reference dose for the γ-test was the dose to the static phantom. The scatter plot compares the 
γ failure rate in the measured doses with the γ failure rate in the reconstructed doses for the 32 combinations of 
VMAT treatment plans, motion trajectories, and tracking or no tracking. The line of unity is shown in black. 
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